- Price
- $240.74
- Day
- -1.27%
- Mkt Cap
- $15.12B
- 52W Range
- $125.79 – $266.38
- Volume
- 2.21M
- Beta
- 0.32
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.
Read full article
Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Read full article
Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.
Read full article
Engineers Gate Manager LP cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 93.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,287 shares of the specialty pharmaceutical company's stock after selling 86,703 shares
Read full article
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Read full article
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare disease DUBLIN, Sept. 15, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront.
Read full article
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Read full article
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Read full article
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m.
Read full article
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Read full article